WallStSmart

DexCom Inc (DXCM)vsModular Medical Inc (MODD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DXCM leads profitability with a 20.1% profit margin vs 0.0%. DXCM earns a higher WallStSmart Score of 72/100 (B).

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 4.3Quality: 7.0
Piotroski: 5/9Altman Z: 2.67

MODD

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -12.19

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

MODD2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

DXCM3 concerns · Avg: 4.0/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
33.0x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.2x4/10

Trading at 12.2x book value

MODD4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : MODD

The strongest argument for MODD centers on Price/Book, Debt/Equity.

Bear Case : DXCM

The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : MODD

The primary concerns for MODD are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

DXCM profiles as a mature stock while MODD is a value play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.45 — expect wider price swings.

DXCM is growing revenue faster at 13.1% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 26/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Modular Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Modular Medical, Inc., a development-stage medical device company, focuses on the design, development and marketing of insulin pumps for people with insulin-dependent diabetes. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?